Abstract Vancomycin is the standard antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. While daptomycin is approved for MRSA bacteremia, its effectiveness in osteoarticular infections (OAIs) has not been established. A 1:2 nested case-control study of adult patients with MRSA OAIs admitted to an academic center from 2005 to 2010 was carried out. Clinical outcomes and drug toxicity in patients treated with daptomycin versus vancomycin were compared. Twenty patients with MRSA OAIs treated with daptomycin were matched to 40 patients treated with vancomycin. The median age of the patients was 52 years (range, 25-90), and 40 (67 %) were male. Most patients had osteomyelitis (82 %), predominantly from a contiguous source (87 %). Forty percent were diabetics. Diabetic patients were more likely to receive vancomycin than daptomycin [20 (50 %) vs. 4 (20 %); p =0.03]. Vancomycin was more often combined with antibiotics other than daptomycin [22 (55 %) vs. 5 (25 %); p =0.03]. The median total antibiotic treatment duration was 48 (daptomycin) vs. 46 days (vancomycin) (p =0.5). Ninety percent of daptomycin-treated patients had previously received vancomycin for a median of 14.5 days (range, 2-36). Clinical success rates were similar between daptomycin and vancomycin at 3 months [15 (75 %) vs. 27 (68 %); p =0.8] and 6 months [14 (70 %) vs. 23 (58 %); p =0.5], even after propensity scorebased adjustment for antibiotic assignment. The frequency of adverse events was similar between treatment groups [1 (5 %) vs. 7 (18 %); p =0.2]. Daptomycin and vancomycin achieved similar rates of clinical success and drug tolerability. Daptomycin is a reasonable alternative for treating MRSA OAIs, particularly in patients where therapy with vancomycin has not been well tolerated.
vs. 23 (58 %); p =0.5], even after propensity scorebased adjustment for antibiotic assignment. The frequency of adverse events was similar between treatment groups [1 (5 %) vs. 7 (18 %); p =0.2]. Daptomycin and vancomycin achieved similar rates of clinical success and drug tolerability. Daptomycin is a reasonable alternative for treating MRSA OAIs, particularly in patients where therapy with vancomycin has not been well tolerated.
Background
Staphylococcus aureus is the most common cause of osteoarticular infections (OAIs) [1] . Appropriate antibiotic therapy is tailored to the antibiotic resistance profile of the individual S. aureus isolate. Methicillin-resistant S. aureus (MRSA) is typically treated with vancomycin, a glycopeptide antibiotic. Vancomycin, however, has the potential to cause significant nephrotoxicity [2] . The emergence of vancomycinintermediate S. aureus (VISA) has further limited its use in many settings [3] .
Daptomycin is the first of a new class of antibiotics, the cyclic lipopeptides, and has a mechanism of action unlike any other currently marketed antibiotic [4] . It is bactericidal and active against otherwise drug-resistant Gram-positive bacteria. Daptomycin is also well-tolerated and convenient to administer, making it a desirable option for outpatient parenteral antibiotic therapy [5] . It is currently approved in the United States for the treatment of skin and soft tissue infections, bloodstream infections, and right-sided endocarditis. Since its initial introduction in 2003, daptomycin has been increasingly used in the management of OAIs [6] . Common reasons for using daptomycin in MRSA OAIs include intolerance to or failure of the standard antibiotic treatment. Vancomycin failures have been attributed to poor bone penetration, increasing minimum inhibitory concentrations (MICs), and difficult-totitrate dosing requiring frequent monitoring of drug levels [7] .
A number of case series and analyses of registries have demonstrated that daptomycin can achieve high cure rates in OAIs [6, [8] [9] [10] . Gonzalez-Ruiz and colleagues reported findings from 64 cases of osteomyelitis seen in Europe, where success was achieved in 80 % [11] . Few studies have compared daptomycin versus vancomycin for the treatment of OAIs. Moenster et al. published a case-control study of 51 patients with osteomyelitis but did not exclusively focus on MRSA infections; patients treated with daptomycin had significantly fewer recurrent infections 6 months after completing intravenous antibiotics [12] . Lalani et al. performed a post hoc subanalysis of OAIs identified in a randomized controlled trial of patients with staphylococcal bloodstream infection and right-heart endocarditis, and found higher success rates in the daptomycin group [13] .
Our objective was to analyze data from a retrospective cohort of OAIs and compare patient characteristics, clinical manifestations, and outcomes of MRSA OAIs treated with either daptomycin or vancomycin.
Methods
Study design, setting, and inclusion/exclusion criteria This was a 1:2 nested case-control study performed at BarnesJewish Hospital (BJH), a 1,250-bed tertiary care hospital. We included adult patients admitted to BJH between August 1, 2005 and July 31, 2010 who were diagnosed with MRSA osteomyelitis or septic arthritis per tissue or fluid culture (with documentation of the infection in their medical records). Cases and controls were selected based on antibiotic assignment. All patients with MRSA osteomyelitis or septic arthritis treated with daptomycin during the specified time frame were included as cases, regardless of the duration of treatment. We matched controls treated with vancomycin to cases by month and year of hospital admission. No further matching was performed in order to allow the analysis of potential factors influencing antibiotic selection. We excluded patients with: (1) polymicrobial infections, (2) persistent bacteremia (>72 h), and (3) concurrent endocarditis. Eligible patients were identified using the hospital's outpatient intravenous antibiotic registry. The diagnosis of MRSA osteomyelitis or septic arthritis was confirmed by microbiology records for all patients in the study.
Data collection, outcomes, and statistical analysis
We collected demographic characteristics, comorbidities, clinical presentation, diagnostic work-up including laboratory values, microbiology (including MICs for daptomycin and vancomycin when available), and imaging studies, as well as the type and duration of antibiotic treatment from hospital electronic medical records. The presence of orthopedic hardware at the site of infection, including prosthesis and internal or external fixation, was identified. Follow-up laboratory values and imaging studies as well as outcomes, including adverse events, were identified through review of outpatient electronic medical records from the infectious disease clinic. The mean serum vancomycin trough concentrations encompassing the entire treatment period and averaged over all measurements were calculated for all patients receiving vancomycin, as well as for those pre-treated with vancomycin prior to starting daptomycin. For daptomycin, creatine phosphokinase (CPK) levels obtained during therapy were reviewed to determine a peak level. The reasons for changing antibiotic therapy (e.g., clinical failure, microbiological failure including the discovery of VISA, toxicity-related discontinuation, or problems stemming from convenience or insurancerelated issues) were documented. At our institution, an S . aureus strain with an elevated vancomycin MIC of 4 to 8 mcg/mL is considered to be VISA.
We compared drug toxicity, medical/surgical management, and clinical outcomes in patients treated with daptomycin versus vancomycin. This comparison was based on the following endpoints: (1) Treatment success , which was defined as resolution of signs and symptoms and improvement of function and normalization of inflammatory markers (when available) and no repeat surgery for osteomyelitis after discharge and no readmission related to the osteomyelitis within 8 weeks (of starting antibiotics) and (2) Tolerability of antibiotic treatment, including occurrence of and readmission for adverse events and early discontinuation of the prescribed antibiotic if associated with adverse events. Treatment success rates were calculated both with the inclusion of those lost to follow-up as failures and excluding those lost to follow-up altogether. Clinical outcomes were compared, adjusting for propensity to antibiotic assignment using propensity score methods. For this purpose, we created a regression model predicting assignment to either of the study antibiotics. A weighted score was assigned to patients in the daptomycin (1/probability) and vancomycin groups [1/(1 − probability)]. Then, in a logistic regression to elicit predictors of clinical success at 6 months, we included variables that had a p <0.1 in the univariate analysis along with the weighted propensity score. Adverse events included Clostridium difficile infection, bloodstream infection attributed to a central venous catheter, elevated liver function tests, elevated CPK, nephrotoxicity (serum creatinine ≥1.5 mg/dL), leukopenia (white blood cell count ≤3.5 cells per μL), and a rash and/or allergic reaction.
Statistical analysis was conducted using SPSS version 18 (SPSS Inc., Chicago, IL). This study was approved by the Washington University Human Research Protection Office.
Results
We identified 20 patients with MRSA OAIs treated with daptomycin and 237 treated with vancomycin during the study period. Of the patients treated with vancomycin, 40 were matched as controls to the 20 daptomycin cases by month and year of hospital admission. Overall, the patients' median age was 52 years (range, 25-90 years), 40 (67 %) out of 60 were male, and 40 (67 %) were white (Table 1) . Most patients had osteomyelitis (82 %) and a contiguous source of infection (87 %). Eleven patients (18 %) had isolated septic arthritis, whereas an overlapping diagnosis between septic arthritis and osteomyelitis was encountered in 10/60 (17 %). Forty percent of the total study population was diabetic. Eight of 60 (13 %) patients had renal insufficiency (serum creatinine >1.5 mg/dL) on admission. Seven (12 %) had peripheral vascular disease.
The mean daptomycin dose encountered in the cases was 6.0 mg/kg (±0.6 mg/kg), in accordance with standard dosing of the drug for bloodstream infection. The mean serum vancomycin trough concentration achieved in controls receiving only vancomycin was 17.8 μg/mL, in accordance with the recommended target concentration of 15-20 μg/mL for MRSA OAIs [3] . In the vancomycin group, there were more diabetic patients compared to the daptomycin group The median treatment duration was 39 days for daptomycin (range 3-112) versus 46 days for vancomycin (range 21-135) (p =0.01). However, most patients in the daptomycin group had initially been treated with vancomycin (18/20; 90 %), receiving vancomycin for a median of 14.5 days (range 2-36) prior to switching to daptomycin. Out of 20 patients in the daptomycin group, 14 (70 %) received ≥4 weeks of treatment with daptomycin and only two (10 %) received ≤1 week. Taking into account pre-treatment with vancomycin, the median total antibiotic treatment duration was 48 days for the daptomycin group (range 26-118) versus 46 days for the vancomycin group (range 21-135) (p =0.5). Patients receiving daptomycin underwent more surgeries during the initial hospital admission than patients on vancomycin (1.8±0.8 vs. 1.4±0.6; p =0.04).
Treatment success was achieved in 70 % (42/60) of all patients at 3 months and in 62 % (37/60) at 6 months after completing intravenous antibiotics when loss to follow-up was considered equivalent to failure. Documented success rates were similar between daptomycin and vancomycin at 3 months [15/20 ( The frequency of adverse events did not differ significantly between treatment groups [1 (5 %) with daptomycin vs. 7 (18 %) with vancomycin; p =0.2], although patients in the daptomycin group experienced three-fold fewer adverse events than those receiving vancomycin. The single patient with an adverse event reported in the daptomycin group experienced a CPK elevation meeting criteria for discontinuation of the drug (CPK >5 times the upper limit of normal in the presence of signs of myopathy or CPK ≥10 times the upper limit of normal in the absence of symptoms). Six out of seven patients with adverse events in the vancomycin group had nephrotoxicity attributed to that antibiotic.
Of the 20 patients in the daptomycin group, 18 (90 %) were pre-treated with vancomycin. The reasons for replacing vancomycin with daptomycin were rash (including red man syndrome) (5/20; 25 %), failure to achieve therapeutic vancomycin levels ( 
Discussion
Daptomycin first became available in 2003 as an option to treat Gram-positive bacteria such as S . aureus, but is not currently U.S. Food and Drug Administration (FDA)-approved for OAIs. Yet, it has been increasingly used to treat OAIs, particularly in the setting of MRSA, and is frequently used as an alternative to vancomycin. Little evidence exists to support this practice. In this small nested case-control study with the comparison of outcomes of patients with MRSA bone and joint infections adjusted for propensity to antibiotic assignment, we found that daptomycin and vancomycin achieved similar rates of clinical success and drug tolerability. Based on these data, daptomycin is a reasonable alternative to vancomycin for treating MRSA bone and joint infections.
Head-to-head clinical trials of different antibiotics for OAIs are scarce [14] . Current practices are, therefore, driven by lower-quality comparisons or expert opinion. For a subset of OAIs, prosthetic joint infections, the Infectious Diseases Society of America (IDSA) has recently issued the first national management guidelines [15] . In those guidelines, daptomycin is mentioned as an alternative treatment option for staphylococcal and enterococcal infections. In a separate IDSA guideline on MRSA infections, both vancomycin and daptomycin are named as possible agents for treating bone and joint infections. While daptomycin has been shown to be equivalent to vancomycin and other comparators in a landmark randomized controlled trial on staphylococcal bloodstream infections and endocarditis [16] , no such data exist for orthopedic infections. Lalani and colleagues used the data from the study mentioned above to conduct a post hoc analysis of patients who subsequently developed OAIs. Their report was limited by small numbers (i.e., a total of 11 patients with MRSA OAIs) [13] . Another more recent study by Moenster and colleagues performed at a Veterans Affairs hospital compared daptomycin and vancomycin for OAIs but included only a subset of 23 patients with infections caused by MRSA [12] . The authors noted fewer recurrences of infection in the daptomycin group, although these findings may have limited generalizability to more heterogeneous, non-veteran populations. As in our study, the majority of patients eventually treated with daptomycin had initially started on vancomycin; reasons leading to changes in antibiotics were not reported. In contrast, our study focused on MRSA infections, which, in our experience, represent the primary indication for using daptomycin, and included a larger sample size and a more diverse population than previous studies. We also believe that our findings are among the first to demonstrate the wide range of reasons for switching from vancomycin to daptomycin in clinical practice. In our relatively small study, outcomes were similar across the groups, even after antibiotic assignment was adjusted for propensity scores. This is particularly interesting given that patients in the daptomycin group were often pre-treated with vancomycin and more complex (they were more likely to have hardware-associated infection and required more surgeries). While the propensity for assignment to daptomycin versus vancomycin treatment was not found to predict clinical outcomes, a history of antibiotic allergy was predictive of poorer outcomes. A history of antibiotic allergy may be a marker for treatment with secondline agents, resulting in a greater likelihood of refractory disease. In fact, some evidence indicates that a history of antibiotic allergy impacts patient outcomes [17] . Lastly, more diabetic patients were seen in the vancomycin group than those on daptomycin; this may be a reflection of the general acceptance of vancomycin as part of a combination regimen for diabetic OAIs. No robust evidence argues against the use of daptomycin in diabetic patients [18] . Future studies of the comparative effectiveness of daptomycin versus other antimicrobial agents will likely be compromised by the fact that, in our experience, daptomycin is rarely initiated as the first-line therapy for osteoarticular MRSA infections, supporting the need for randomized controlled trials. One major reason for deferring the use of daptomycin is the anticipated cost of treatment, which is also influenced by the prolonged treatment duration required to achieve cure in bone and joint infections. In the USA, the average cost of therapy associated with daptomycin is more than 30 times that of vancomycin [19] . Among the limitations of our study are the relatively small number of cases, which reflects the still relatively uncommon use of daptomycin at our institution, and the single-center and retrospective design. Follow-up was limited to 6 months after intravenous treatment completion; however, some data suggest that most infection recurrences are identified in the first few months after treatment, and more extended observation for endpoints may not be necessary [20] .
Conclusions
Our findings support daptomycin as a useful and welltolerated option for treating methicillin-resistant Staphylococcus aureus (MRSA), one of the most common pathogens associated with osteoarticular infections (OAIs). Outcomes of daptomycin-treated infections were similar to those treated with vancomycin, even for pre-treated and complex patients, and for those who had experienced toxicities related to the prior antibiotic.
